Chemokines as Prognostic Factor in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Chemokine receptor CXCR4 overexpression indicates poor prognosis in colorectal cancer patients, significantly reducing overall and disease-free survival. This systematic review highlights CXCR4 as a potential prognostic biomarker for colorectal cancer.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Chemokines and their receptors are integral to tumor progression, influencing angiogenesis, apoptosis, and metastasis.
- Tumor-infiltrating immune cells and tumor cells express chemokine receptors within the tumor microenvironment.
- Altered chemokine and receptor expression is common in solid cancers, impacting patient outcomes, particularly in colorectal cancer.
Purpose Of The Study
- To systematically review and meta-analyze the role of chemokines as prognostic biomarkers in colorectal cancer (CRC).
- To investigate the association between the expression of 25 specific chemokines and patient survival outcomes in CRC.
Main Methods
- A systematic literature search was performed across PubMed, CENTRAL, and Web of Science databases.
- Data from 31 publications, analyzing chemokine expression in CRC tissue and patient survival, were included.
- Hazard ratios (HR) for overall survival (OS) and disease-free survival (DFS) were calculated using random-effects meta-analysis, with risk of bias assessed by Quality in Prognosis Studies.
Main Results
- Overexpression of chemokine receptor CXCR4 was significantly associated with reduced overall survival (HR = 2.70) and disease-free survival (HR = 2.68) in CRC patients.
- The risk of bias for studies evaluating CXCR4 was rated as low.
- Results for other chemokines were either heterogeneous or based on limited studies.
Conclusions
- CXCR4 overexpression is a significant indicator of diminished overall and disease-free survival in colorectal cancer patients.
- CXCR4 emerges as a promising prognostic biomarker for colorectal cancer.
- Further research is warranted to explore CXCR4 and its antagonists as potential therapeutic targets in CRC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...